JPH02172915A - Cerebral cell metabolism improving composition - Google Patents
Cerebral cell metabolism improving compositionInfo
- Publication number
- JPH02172915A JPH02172915A JP32646288A JP32646288A JPH02172915A JP H02172915 A JPH02172915 A JP H02172915A JP 32646288 A JP32646288 A JP 32646288A JP 32646288 A JP32646288 A JP 32646288A JP H02172915 A JPH02172915 A JP H02172915A
- Authority
- JP
- Japan
- Prior art keywords
- cell metabolism
- chain amino
- improving composition
- metabolism improving
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000019522 cellular metabolic process Effects 0.000 title claims abstract description 10
- 230000002490 cerebral effect Effects 0.000 title abstract 4
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960000310 isoleucine Drugs 0.000 claims abstract description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004474 valine Substances 0.000 claims abstract description 4
- 210000004958 brain cell Anatomy 0.000 claims description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 3
- 230000003933 intellectual function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、新規な脳細胞代謝改善組成物に関するもので
あり、脳細胞の老化防止に有用な組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a novel composition for improving brain cell metabolism, and relates to a composition useful for preventing aging of brain cells.
従来より、脳細胞の代謝が低下することがひとつの原因
とされている老人性痴呆症に対する治療方法の開発が望
まれており、その他にも肝臓疾患による肝性脳症や、脳
梗塞後の後遺症によるものなど脳障害に関する問題が、
重要視されてきている。It has long been desired to develop a treatment method for senile dementia, which is thought to be caused by a decline in brain cell metabolism, as well as hepatic encephalopathy caused by liver disease and sequelae after cerebral infarction. Problems related to brain disorders such as those caused by
It is becoming important.
世界最高水準の長寿国となったわが国において、痴呆老
人に対する対策は、特に深刻である。現在のところ、こ
れらの治療については、それぞれの基礎疾患についての
対処療法が中心となっており、特に血管性痴呆の場合に
は、血管拡張剤による治療が中心となっている。In Japan, which has achieved one of the world's highest levels of longevity, measures against elderly people with dementia are particularly serious. At present, these treatments center on treatments for each underlying disease, and in particular, in the case of vascular dementia, treatment with vasodilators is the main focus.
痴呆性老人の出現率は、高齢になるにしたがって高くな
り、今後ますます高齢化・長寿社会が進むと予想され、
社会的にも、痴呆症に対する対策は急務である。The incidence of elderly people with dementia increases as people get older, and it is expected that society will continue to age and live longer.
Socially, there is an urgent need to take measures against dementia.
アミノ酸を含有する組成物として、分枝鎖アミノ酸に関
しては、筋肉運動の機能を向上させることから、これを
含有する飲料が開発されている（特開昭５８−１６５７
７４号公報参照）。また、アラニン、オルニチンまたは
アラニン、グルタミンを含有する抗アルコール性肝障害
組成物も開発されている（特開昭６１−５０９１７号ま
たは特開昭６３−５４３２０号公報参照）。Regarding compositions containing amino acids, beverages containing branched chain amino acids have been developed because they improve the function of muscle exercise (Japanese Patent Laid-Open No. 58-1657).
(See Publication No. 74). Furthermore, anti-alcoholic liver damage compositions containing alanine, ornithine, alanine, and glutamine have also been developed (see JP-A-61-50917 or JP-A-63-54320).
脳細胞の代謝改善効果を有し、脳細胞の老化防止に有用
な組成物の開発が望まれている。It is desired to develop a composition that has the effect of improving the metabolism of brain cells and is useful for preventing aging of brain cells.
脳細胞に限らず、生体の細胞の代謝の調節機構において
、アミノ酸は重要な役割を担っている。Amino acids play an important role in the regulatory mechanism of metabolism not only in brain cells but also in living cells.
本発明者らは、アミノ酸に対して、広く検討を行なった
結果、分枝鎖アミノ酸が脳細胞の代謝改善効果を有する
ことを見い出し、本発明を完成するに到った。即ち、本
発明は、分枝鎖アミノ酸を含有する脳細胞代謝改善組成
物である。The present inventors have extensively studied amino acids, and as a result, have discovered that branched chain amino acids have the effect of improving brain cell metabolism, and have completed the present invention. That is, the present invention is a brain cell metabolism improving composition containing a branched chain amino acid.
分枝鎖アミノ酸としては、バリン、ロイシン、イソロイ
シンの３種があり、本発明の組成物は、これらのアミノ
酸の少な（とも１種を含有するものである。アミノ酸は
Ｌ一体、Ｄ一体、ＤＬ−体を問わないが、天然に存在す
るという点でＬ一体が好ましい。There are three types of branched chain amino acids: valine, leucine, and isoleucine, and the composition of the present invention contains at least one type of these amino acids. -Although it does not matter what kind of body it is, L monolithic is preferable because it exists naturally.
分枝鎖アミノ酸は、遊離の形態でも塩の形態でもよく、
ペプチドの形でもよい。Branched chain amino acids can be in free form or in salt form;
It may also be in the form of a peptide.
成人１日当りの分枝鎖アミノ酸の摂取量は、１〜２０ｇ
が望ましいが、摂取する人の体重等により決定すればよ
い。The daily intake of branched chain amino acids for adults is 1 to 20 g.
is desirable, but it may be determined based on the weight of the person taking it.
本発明の組成物は、摂取量を保証できれば、医薬品また
は食品の形態で提供できる。例えば医薬品としては、散
剤、顆粒、錠剤、液剤等などであり、食品としてはドリ
ンク類が好ましい。The composition of the present invention can be provided in the form of a drug or food, as long as the amount of intake can be guaranteed. For example, pharmaceuticals include powders, granules, tablets, liquids, etc., and foods include drinks.
本発明の組成物は、ある程度の長時間摂取を続けること
により、その効果は特に顕著に認められる。また、脳細
胞の代謝改善効果のみならず、脳細胞の老化防止に対し
ても有用な効果を有している。The effects of the composition of the present invention are particularly noticeable when ingested for a certain period of time. In addition, it has a useful effect not only on improving metabolism of brain cells but also on preventing aging of brain cells.
尚、本組成物は、分枝鎖アミノ酸以外に、本発明の目的
を逸脱しない限り、他のアミノ酸の共存も可能である。In addition to the branched chain amino acids, other amino acids may also be present in the present composition as long as they do not depart from the purpose of the present invention.
以下、実施例により本発明を更に具体的に説明する。Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例１
バリン、ロイシン、イソロイシンをモル比で１：ｌ：１
で含有する顆粒状組成物５ｇを調製し、老人性痴呆症の
患者５名に対し、３箇月間摂取させ同時に知的訓練を行
なった。Example 1 Valine, leucine, and isoleucine in a molar ratio of 1:l:1
5 g of a granular composition containing the above was prepared and ingested by five patients with senile dementia for three months while simultaneously undergoing intellectual training.
知的機能検査の方式は、長谷用式簡易知的機能検査を採
用し、摂取前後の点数により、効果を測定した。結果を
下表に示す。The intellectual function test method used was Hase's simple intellectual function test, and the effects were measured by scores before and after intake. The results are shown in the table below.
表
以上の結果より、本発明の組成物の摂取を続けることに
より知的機能の回復がみられ、脳細胞の代謝改善効果が
あったと考えられる。From the results shown in the table above, it is considered that by continuing to take the composition of the present invention, recovery of intellectual function was observed, and there was an effect of improving brain cell metabolism.
（発明の効果〕
以上から明らかなように、本発明によれば実用性の高い
優れた脳細胞代謝改善剤・老化防止剤を提供することが
でき、本発明は極めて有用である。(Effects of the Invention) As is clear from the above, the present invention can provide a highly practical and excellent brain cell metabolism improving agent/antiaging agent, and the present invention is extremely useful.
Claims (1)
代謝改善組成物。 ２）分枝鎖アミノ酸が、バリン、ロイシンおよびイソロ
イシンの中の少くとも１種である請求項１記載の組成物
。[Scope of Claims] 1) A brain cell metabolism improving composition characterized by containing a branched chain amino acid. 2) The composition according to claim 1, wherein the branched chain amino acid is at least one of valine, leucine and isoleucine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32646288A JPH02172915A (en) | 1988-12-23 | 1988-12-23 | Cerebral cell metabolism improving composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32646288A JPH02172915A (en) | 1988-12-23 | 1988-12-23 | Cerebral cell metabolism improving composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02172915A true JPH02172915A (en) | 1990-07-04 |
Family
ID=18188079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP32646288A Pending JPH02172915A (en) | 1988-12-23 | 1988-12-23 | Cerebral cell metabolism improving composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02172915A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0605742A1 (en) * | 1992-06-26 | 1994-07-13 | KISLYAKOVA, Nonna Dmitrievna | Agent with adaptogenic activity |
| WO2004058243A1 (en) * | 2002-12-26 | 2004-07-15 | Ajinomoto Co., Inc. | Inhibitor for liver cancer onset and progress |
| WO2005072721A1 (en) * | 2004-01-28 | 2005-08-11 | Ajinomoto Co., Inc. | Medicinal composition for preventing or treating neural disorders accompanying topical lowering in brian blood flow |
| WO2007043363A1 (en) | 2005-10-12 | 2007-04-19 | Otsuka Pharmaceutical Factory, Inc. | Composition for use in prevention of hypoglycemic condition |
| WO2008044691A1 (en) | 2006-10-10 | 2008-04-17 | Otsuka Pharmaceutical Factory, Inc. | Antidepressant agent |
| KR101301037B1 (en) * | 2006-07-03 | 2013-08-28 | 가부시키가이샤 니폰 배리어 프리 | Antiaging agent |
-
1988
- 1988-12-23 JP JP32646288A patent/JPH02172915A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0605742A1 (en) * | 1992-06-26 | 1994-07-13 | KISLYAKOVA, Nonna Dmitrievna | Agent with adaptogenic activity |
| EP0605742A4 (en) * | 1992-06-26 | 1996-01-03 | Nonna Dmitrievna Kislyakova | Agent with adaptogenic activity. |
| JP2010180244A (en) * | 2002-12-26 | 2010-08-19 | Ajinomoto Co Inc | Inhibitor for liver cancer onset/progress |
| JPWO2004058243A1 (en) * | 2002-12-26 | 2006-04-27 | 味の素株式会社 | Liver cancer development / proliferation inhibitor |
| CN1329030C (en) * | 2002-12-26 | 2007-08-01 | 味之素株式会社 | Inhibitor for liver cancer onset and progress |
| WO2004058243A1 (en) * | 2002-12-26 | 2004-07-15 | Ajinomoto Co., Inc. | Inhibitor for liver cancer onset and progress |
| JP5074661B2 (en) * | 2002-12-26 | 2012-11-14 | 味の素株式会社 | Liver cancer development / proliferation inhibitor |
| US9271521B2 (en) | 2002-12-26 | 2016-03-01 | Ajinomoto Co., Inc. | Inhibitor for liver cancer onset and progress |
| WO2005072721A1 (en) * | 2004-01-28 | 2005-08-11 | Ajinomoto Co., Inc. | Medicinal composition for preventing or treating neural disorders accompanying topical lowering in brian blood flow |
| JPWO2005072721A1 (en) * | 2004-01-28 | 2007-09-06 | 味の素株式会社 | Pharmaceutical composition for prevention or treatment of nervous system disorders associated with decreased local cerebral blood flow |
| WO2007043363A1 (en) | 2005-10-12 | 2007-04-19 | Otsuka Pharmaceutical Factory, Inc. | Composition for use in prevention of hypoglycemic condition |
| KR101301037B1 (en) * | 2006-07-03 | 2013-08-28 | 가부시키가이샤 니폰 배리어 프리 | Antiaging agent |
| WO2008044691A1 (en) | 2006-10-10 | 2008-04-17 | Otsuka Pharmaceutical Factory, Inc. | Antidepressant agent |
| US9060979B2 (en) | 2006-10-10 | 2015-06-23 | Otsuka Pharmaceutical Factory, Inc. | Antidepressant |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2608483T3 (en) | Improved method of administration of beta-hydroxy-beta-methylbutyrate (HMB) | |
| AU627041B2 (en) | Improved nutritional formulation for the treatment of renal disease | |
| JP4280310B2 (en) | Amino acid composition | |
| JP5555401B2 (en) | Hepatitis C virus-positive human liver cirrhosis patient liver cancer occurrence / proliferation inhibitor | |
| JPH02172915A (en) | Cerebral cell metabolism improving composition | |
| JPWO2006080086A1 (en) | Composition for recovery or prevention of fatigue of central nervous system | |
| Gaull | Pathogenesis of maple-syrup-urine disease: observations during dietary management and treatment of coma by peritoneal dialysis | |
| AU2001270980B2 (en) | Food supplement with a slimming effect | |
| JP2006193435A (en) | Fatigue-improving agent | |
| JP5098198B2 (en) | Copper compound composition | |
| WO2004017955A1 (en) | L-arginine containing pharmaceutical composition | |
| JP2006045215A (en) | Zinc-containing internal liquid medicine | |
| US20080242727A1 (en) | Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass | |
| JPH04501724A (en) | Treatment of osteoporosis | |
| JP3553992B2 (en) | Metabolic regulator | |
| US20050239888A1 (en) | Pharmaceutical compositions containing keto-acids for endoperitoneal administration | |
| JP4959864B2 (en) | Glutamate-containing solution | |
| JP2017070271A (en) | Food product or supplement | |
| Buttner et al. | The effect of fluoride administration on fluoride deposition in tissues and on serum cholesterol in the rat | |
| RU2160589C1 (en) | Agent for reducing alcoholic drunkenness, preventing and eliminating alcohol intoxication and hangover syndrome and method for reducing alcoholic drunkenness, preventing and eliminating alcohol intoxication and hangover syndrome using this agent | |
| JP4847732B2 (en) | Cold remedy | |
| Bozek et al. | Sinemet in Parkinson's disease: efficacy with and without food | |
| JPS60199365A (en) | Composition containing amino acid | |
| JP2941337B2 (en) | Sports Drink | |
| JPH10287551A (en) | Liquid agent for internal use improved in unpleasant flavor of amino acid |